United States· US:0597-0182_16f275d5-7526-4e7a-8776-665a9a6ae37a
Glyxambi
A linagliptin and empagliflozin product containing empagliflozin; linagliptin, registered in United States by Boehringer Ingelheim Pharmaceuticals, Inc.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Linagliptin and empagliflozin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Linagliptin and empagliflozin · ATC A10BD19
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- EMPAGLIFLOZIN; LINAGLIPTIN
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- A10BD19
- ATC class
- Linagliptin and empagliflozin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc11059701823030 TABLET, FILM COATED in 1 BOTTLE (0597-0182-30)
- ndc11059701823930 BLISTER PACK in 1 CARTON (0597-0182-39) / 1 TABLET, FILM COATED in 1 BLISTER PACK
- ndc11059701829090 TABLET, FILM COATED in 1 BOTTLE (0597-0182-90)
- ndc110597-0182-30
- ndc110597-0182-39
- ndc110597-0182-90
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linagliptin and empagliflozin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLYXAMBIBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- PolandGlyxambiBoehringer Ingelheim International GmbH
- SpainGLYXAMBI 10 MG/5 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
- FinlandGlyxambiBoehringer Ingelheim International GmbH
- United KingdomGlyxambi 10mg/5mg tabletsBoehringer Ingelheim Ltd
- IrelandGlyxambi 10 mg/5 mg film-coated tabletsBoehringer Ingelheim International GmbH
- IcelandGlyxambiBoehringer Ingelheim International GmbH*
- NetherlandsGlyxambi 10 mg/ 5 mg, filmomhulde tablettenBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Glyxambi
- Liechtenstein · Glyxambi
- Norway · Glyxambi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/26fd9ae5-12eb-4c30-9175-804055077abe GET /v1/drugs/26fd9ae5-12eb-4c30-9175-804055077abe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "10; 5",
"substance": "EMPAGLIFLOZIN; LINAGLIPTIN",
"productndc": "0597-0182",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1",
"application_number": "NDA206073",
"marketing_category": "NDA"
}See everything about linagliptin and empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.